| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTP4A3 |
| Uniprot No | O75365 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-170aa |
| 氨基酸序列 | MARMNRPAPV EVSYKHMRFL ITHNPTNATL STFIEDLKKY GATTVVRVCE VTYDKTPLEK DGITVVDWPF DDGAPPPGKV VEDWLSLVKA KFCEAPGSCV AVHCVAGLGR APVLVALALI ESGMKYEDAI QFIRQKRRGA INSKQLTYLE KYRPKQRLRF KDPHTHKTRC |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTP4A3(PRL-3)重组蛋白的3-4篇参考文献及其简要摘要：
1. **《PRL-3 promotes cell motility and invasion through PI3K/AKT signaling in hepatocellular carcinoma》**
- **作者**: Guo et al. (2020)
- **摘要**: 该研究通过重组PTP4A3蛋白实验，揭示了其在肝癌细胞中通过激活PI3K/AKT信号通路促进迁移和侵袭的分子机制，表明其作为治疗靶点的潜力。
2. **《Phosphatase activity and oncogenic potential of PRL-3 in colorectal cancer》**
- **作者**: Saha et al. (2005)
- **摘要**: 通过重组PRL-3蛋白的体外功能分析，发现其磷酸酶活性对结直肠癌细胞增殖和转移的关键作用，为开发小分子抑制剂提供依据。
3. **《PRL-3: A metastasis-associated phosphatase in cancer》**
- **作者**: Bardelli et al. (2003)
- **摘要**: 早期研究利用重组PRL-3蛋白验证其与肿瘤转移的关联，发现其在多种癌症中高表达，并与患者预后不良相关。
4. **《Recombinant PRL-3 ectopic expression enhances angiogenesis via integrin β1 signaling》**
- **作者**: Zhang et al. (2018)
- **摘要**: 通过重组蛋白实验证明，PTP4A3通过调控整合素β1信号促进血管生成，为靶向肿瘤微环境提供新视角。
以上研究均围绕重组PTP4A3蛋白的功能展开，涵盖其在癌症转移、信号通路及治疗靶点探索中的应用。
PTP4A3. also known as Protein Tyrosine Phosphatase 4A3 or PRL-3 (Phosphatase of Regenerating Liver-3), is a member of the PRL subfamily of dual-specificity phosphatases. It is encoded by the *PTP4A3* gene and plays a critical role in cellular signaling pathways, particularly those regulating cell proliferation, migration, and survival. Unlike classical protein tyrosine phosphatases, PRL-3 primarily targets phosphorylated serine/threonine residues, influencing key oncogenic pathways such as the Ras/MAPK and PI3K/AKT cascades. Its overexpression has been strongly implicated in cancer progression, metastasis, and poor clinical outcomes, notably in colorectal, liver, and breast cancers.
Structurally, PTP4A3 contains a conserved phosphatase catalytic domain and a unique C-terminal prenylation motif (CAAX box), which facilitates membrane localization and interaction with signaling complexes. Recombinant PTP4A3 protein is typically produced in *E. coli* or mammalian expression systems, enabling studies on its enzymatic activity, substrate specificity, and interactions. Researchers utilize this recombinant protein to explore its role in tumorigenesis, screen for inhibitory compounds, and develop diagnostic or therapeutic tools. Despite its small size (~20 kDa), PTP4A3’s pleiotropic effects on cellular behavior make it a compelling target for oncology research, though its precise molecular mechanisms remain under investigation. Current studies also investigate its potential as a biomarker for early cancer detection or a druggable target to impede metastatic processes.
×
